Copyright
©The Author(s) 2015.
World J Gastrointest Pharmacol Ther. Nov 6, 2015; 6(4): 145-155
Published online Nov 6, 2015. doi: 10.4292/wjgpt.v6.i4.145
Published online Nov 6, 2015. doi: 10.4292/wjgpt.v6.i4.145
Botox® | Dysport® | Xeomin® | NeuroBloc® Myobloc® | |
Manufacturer | Allergan Inc. Irvine, CA, United States | Ipsen Pharma Boulogne-Billancourt, France | Merz Pharmaceuticals Frankfurt/M, Germany | United States WorldMeds Louisville, KY, United States |
Pharmaceutical preparation | Powder | Powder | Powder | Ready-to-use solution 5000 MU-E/mL |
Storage conditions | Below 8 °C | Below 8 °C | Below 25 °C | Below 8 °C |
Shelf life | 36 mo | 24 mo | 36 mo | 24 mo |
Botulinum toxin type | A | A | A | B |
Clostridium botulinum strain | Hall A | Ipsen strain | Hall A | Bean B |
SNARE target | SNAP25 | SNAP25 | SNAP25 | VAMP |
Purification process | Precipitation and chromatography | Precipitation and chromatography | Precipitation and chromatography | Precipitation and chromatography |
pH-value of the reconstituted preparation | 7.4 | 7.4 | 7.4 | 5.6 |
Stabilisation | Vacuum drying | Freeze-drying (lyophilisate) | Vacuum drying | pH-reduction |
Excipients | Human serum albumin 500 μg/100 MU-vial; NaCl 900 μg/100 MU-vial buffer system | Human serum albumin 125 μg/500 MU-vial; Lactose 2500 μg/100 MU-vial buffer system | Human serum albumin 1000 μg/100 MU-vial; Sucrose 4.7 mg/100 MU-vial buffer system | Human serum albumin 500 μg/mL; Disodium succinate 0.01 mol/L; Sodium chloride 0.1 mol/L; H2O; Hydrochloric acid |
Biological activity | 50/100 MU-A/vial | 500 MU-I/vial | 50/100 MU-M/vial | 1.0/2.5/10.0 kMU-E/vial |
Biological activity in relation to Botox® | 1 | 1:2-1:3 | 1 | 1:40 |
Specific biological activity | 60 MU-EV/ngBNT | 100 MU-EV/ngBNT | 167 MU-EV/ngBNT | 5 MU-EV/ngBNT |
- Citation: Nassri A, Ramzan Z. Pharmacotherapy for the management of achalasia: Current status, challenges and future directions. World J Gastrointest Pharmacol Ther 2015; 6(4): 145-155
- URL: https://www.wjgnet.com/2150-5349/full/v6/i4/145.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v6.i4.145